Kinarus Therapeutics Holding AG
Acquires, develops, and commercializes medicines for rare and specialty diseases.
KNRS | SW
Overview
Corporate Details
- ISIN(s):
- CH1330780979
- LEI:
- 506700VDL70GGMHR5758
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.curatis.com/
- Sector:
- Manufacturing
Description
Formerly Kinarus Therapeutics Holding AG, the company now operates as Curatis Holding AG, a specialty pharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines for rare and specialty care diseases. The company's operations are divided into two segments. The distribution business acquires, licenses, and distributes third-party medicines for orphan and specialty diseases. The development business advances a pipeline of novel drug candidates, prioritizing compounds with existing safety and efficacy data to accelerate development. Key development programs target conditions such as peritumoral brain edema, severe migraine with aura, and medication overuse headache.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-21 07:00 |
Curatis Holding AG announces CHF 1.2 million private placement with strategic i…
|
English | 6.3 KB | ||
| 2025-11-21 01:00 |
Curatis Holding AG announces CHF 1.2 million private placement with strategic i…
|
English | 7.9 KB | ||
| 2025-09-18 07:00 |
FDA minutes confirm positive outcome of meeting on 9. September 2025 Corticore…
|
English | 9.4 KB | ||
| 2025-09-18 02:00 |
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticor…
|
English | 11.0 KB | ||
| 2025-09-18 00:00 |
Investor Presentation
|
English | 1.1 MB | ||
| 2025-09-15 07:00 |
Curatis: Double-digit growth in core business and
development milestone achieve…
|
English | 19.7 KB | ||
| 2025-09-15 02:00 |
Curatis: Double-digit growth in core business and
development milestone achieve…
|
English | 22.5 KB | ||
| 2025-09-05 07:00 |
Curatis expands distribution business with Phoenix Labs with up to CHF 5m addit…
|
English | 6.3 KB | ||
| 2025-09-05 02:00 |
Curatis expands distribution business with Phoenix Labs with up to CHF 5m addit…
|
English | 7.8 KB | ||
| 2025-07-31 06:00 |
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
|
English | 8.0 KB | ||
| 2025-07-31 02:00 |
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
|
English | 9.7 KB | ||
| 2025-05-25 11:31 |
Annual General Meeting of Curatis Holding AG approved all proposals of the Boar…
|
English | 7.1 KB | ||
| 2025-05-24 02:00 |
Annual General Meeting of Curatis Holding AG approved all proposals of the Boar…
|
English | 8.8 KB | ||
| 2025-05-23 07:00 |
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opport…
|
English | 13.1 KB | ||
| 2025-05-23 02:00 |
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opport…
|
English | 15.4 KB |
Automate Your Workflow. Get a real-time feed of all Kinarus Therapeutics Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kinarus Therapeutics Holding AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kinarus Therapeutics Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-25 | N/A | Non-Executive member | Buy | None | 1.11 CHF |
| 2023-10-31 | N/A | Executive member | Sell | None | 4,248.75 CHF |
| 2023-09-07 | N/A | Executive member | Sell | None | 11,713.02 CHF |
| 2023-06-23 | N/A | Executive member | Sell | None | 45,028.85 CHF |
| 2023-06-13 | N/A | Executive member | Sell | None | 38,761.94 CHF |
| 2023-06-05 | N/A | Executive member | Sell | None | 1,417,143.65 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 7,441,035.53 CHF |
| 2022-06-02 | N/A | Non-Executive member | Buy | None | 2,483,942.78 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 922,192.69 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 399,716.30 CHF |
Peer Companies
